Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor ...

Once non-small-cell lung cancer (NSCLC) spreads far and wide, treating it is kind of a balancing act. A cure isn't likely, but you can slow it down. So you aim to relieve your symptoms and improve ...

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...

Small-cell lung cancer represents a highly aggressive neuroendocrine subtype of lung cancer. In distant metastatic or ...

Preliminary results from the AACR 2025 Annual Meeting reveal encouraging clinical responses to the investigational oral agent ...

Opdivo (nivolumab) is a brand-name IV infusion prescribed for non-small cell lung cancer (NSCLC) in some situations. This article covers topics such as side effects, dosage, and how Opdivo works.

Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung cancer (SCLC). "Some cancer types are incredibly difficult to treat, one of ...

may improve the prognostic value for overall survival and could help inform treatment decisions in Non Small Cell Lung Cancer (NSCLC); and how Volition's Nu.Q® H3.1, low-cost immunoassay may be ...

At the European Lung Cancer Congress 2025, held in Paris, France, by the European Society for Medical Oncology ... with non–small cell lung cancer (NSCLC) accounting for 80% of these cases.

Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer ... is a program of the European Society for Medical Oncology (ESMO).